



# BETA DRUGS LIMITED

BDL/PKL/SEC/2023

8<sup>th</sup> May, 2023

To  
The Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, 5th Floor  
Plot no. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai — 400 051.

## SYMBOL-BETA

**Sub: Audited Standalone and Consolidated Financial Results for the half year and year ended on 31<sup>st</sup> March, 2023 under Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015**

Dear Sir/Madam

Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the company at their meeting held on Monday, 8<sup>th</sup> May, 2023 had considered and approved the Audited Standalone and Consolidated Financial Results for the half year and year ended on 31<sup>st</sup> March, 2023.

Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following:

1. Management discussion & Analysis
2. Independent Auditor Report of Consolidated Financial Results alongwith Audited Consolidated Financial Results for the half year and year ended on 31<sup>st</sup> March, 2023.
3. Independent Auditor Report of Standalone Financial Results alongwith Audited Standalone Financial Results for the half year and year ended on 31<sup>st</sup> March, 2023.
4. Declaration for un-modified opinion on Audited Standalone and Consolidated Financial Results for the half year and year ended on 31<sup>st</sup> March, 2023.

The meeting of the Board of Directors commenced at 10.00 a.m. and concluded at 1:05 pm.

This is for your information and appropriate dissemination.

Thanking You  
Yours faithfully  
For Beta Drugs Ltd.

  
Rajni Brar  
Company Secretary



CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- [www.betadrugslimited.com](http://www.betadrugslimited.com)

E-Mail :- [info@betadrugslimited.com](mailto:info@betadrugslimited.com)



# BETA DRUGS LIMITED

## Management Discussion & Analysis

Beta consolidated revenues from operations for FY23 jumped by 24% to Rs. 227.11 crores from Rs. 183.84 crores compared with the same period a year ago. This increase was mainly due to 31% growth in Exports and 24% growth in Own Brand sales. While API sales to third parties grew by 65%.

EBITDA excluding Derma impact increased by 28% to Rs.55.92 crores from Rs. 43.7 crores compared with the year-ago period. While EBITDA margin expanded to 25.04% from 23.8%. Improvement in EBITDA was on account of higher sales of branded products and exports along with the positive impact of backward integration. However, considering the impact on Derma's business the consolidated EBITA stood at Rs 53.88 crores.

Consolidated net profit too increased by 24% to Rs.30.72 crores from Rs.24.8 crores compared with the same period a year ago.

Beta continues to be net debt free, and is more than 3 crores cash positive for this year.

## Management Guidance

Management believes that with strong tailwinds coupled with momentum across all its segments; Own Brands, Exports, API, CDMO & Derma, Beta is poised for strong growth for the next many years. The company is now among the top ten players in the cytotoxic Oncology space and aims to be among top five players in the next three years.

The company expects revenues to double in the next three years. While EBITDA margins are expected to improve further to be in the range of 25%-26%.

With the recent approvals of ANVISA & INVIMA will drive strong sales from exports in the next three years. The company has also started registration in many PICS countries.

Beta has expanded its production facilities in API & Adley formulations plant. The company has added one more line in API (focusing on regulated markets) and another injectable line with two new lyophilizers in the Adley Formulations plant. It has further expanded its oral block. The domestic market will be catered from Adley formulations and Beta plant will be dedicated to regulated markets.

The company has a strong product pipeline of FTLs, NDDS, PARP inhibitors, and TKIs which will be launched in the coming months & years. The dermatology division of the company will also grow at a good pace and will be EBITDA positive in the coming 3-4 months.



CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- [www.betadrugslimited.com](http://www.betadrugslimited.com)

E-Mail :- [info@betadrugslimited.com](mailto:info@betadrugslimited.com)



**KALRA RAI & ASSOCIATES**  
**A Peer Review Firm**  
CHARTERED ACCOUNTANTS

M : +91-98880-66743  
Phone - 0172-4640667  
E-mail : kalrarai@gmail.com  
kalrarai667@hotmail.com

🏠 Head Office : Kothi No. 667, 1st Floor, Sector-43 A, Chandigarh - 160022

**Independent auditor's report (unmodified opinion) on the half yearly consolidated financial results and annual consolidated financial results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for companies**

**INDEPENDENT AUDITOR'S REPORT**

**TO THE BOARD OF DIRECTORS OF**

Beta Drugs Limited  
Village Nandpur,  
Lodhimajra ROad  
Baddi Distt Solan  
H.P.-174101

**Report on the Audit of Consolidated Financial Results**

**Opinion**

We have audited the accompanying consolidated half yearly financial results for the period ended **31<sup>st</sup> March, 2023** and consolidated annual financial results of **Beta Drugs Limited** for the year ended **31<sup>st</sup> March, 2023** (hereinafter referred to as the 'Holding Company') and its subsidiaries **M/s Adley Formulations Private Limited** and **M/s Adley Lab Limited** (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended **31<sup>st</sup> March, 2023**, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements /financial results/ financial information of the subsidiaries, associates and jointly controlled entities, the aforesaid consolidated financial results:

(i) Include the annual financial results of the following entities

- a) **Adley Lab Limited**
- b) **Adley Formulations Pvt Ltd.**

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the half year ended **31<sup>st</sup> March, 2023** as well as the year to date results for the period ended **31<sup>st</sup> March, 2023**.



**Branch Office Mohali :-**

Plot No. 775, Sector-82, JLPL, Mohali, Punjab-160082  
EMAIL : kalrarai@rediffmail.com

**Branch Office Delhi :-**

I-50, 4th Floor, Lagpat Nagar-1, New Delhi - 110024, Ph. : 011-43034803  
EMAIL : advphagunkalra@gmail.com | Cell : +91-77989-06173

## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

## **Board of Directors' Responsibilities for the Consolidated Financial Results**

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

## **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

The consolidated Financial Results include the **audited Financial Results of Adley Lab Limited and Adley Formulations Pvt Ltd**, subsidiaries, whose Financial Statements/Financial Results/ financial information reflect Group's share of total assets of Rs. 64,37,65,565.04/- as at **31<sup>st</sup> March, 2023**, Group's share of total revenue of Rs.34,68,03,126.95/- and Rs. 68,94,97,528.83/- and Group's share of total net



profit/(loss) after tax of Rs. 5,77,11,390.66/- and Rs. 11,90,26,465.13/-for the half year ended **31<sup>st</sup> March, 2023** and for the period from **1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023** respectively, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements/ Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

The Financial Results include the results for the half year ended **31<sup>st</sup> March, 2023** being the balancing figure between the audited figures in respect of the full financial year and the published audited year to date figures up to the **1<sup>st</sup> half year** of the current financial year.

**For KALRA RAI & ASSOCIATES.**  
**Chartered Accountants**  
**(Firm's Registration No. 008859N)**



**LAJPAT RAI KALRA**  
**(Partner)**  
**(Membership Number: 087438)**  
**UDIN: 23087438BGVHEG7749**

**Place: Chandigarh**  
**Date: 08/05/2023**

**BETA DRUGS LIMITED**

Village Nandpur, Lodhimaajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

**Audited Consolidated Financial Results for the year ended on 31st March' 2023**

Particulars	6 Months Ended on 31/03/2023 (Audited)	Year Ended on 31/03/2023 (Audited)	6 Months Ended on 31/03/2022 (Audited)	Year Ended on 31/03/2022 (Audited)
I. Revenue From Operations	1,14,72,31,009.38	2,27,11,35,994.25	95,74,19,333.91	1,83,83,74,346.40
II. Other income	42,72,693.76	75,35,155.30	30,23,489.47	75,68,912.50
III. Total Revenue (I+II)	1,15,15,03,703.14	2,27,86,71,149.55	96,04,42,823.38	1,84,59,43,258.90
IV. Expenses				
a) Cost of Materials Consumed	57,10,10,441.89	1,10,40,21,990.24	48,49,34,030.25	96,20,72,647.56
b) Purchase of Stock-in-Trade	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	(4,92,39,517.17)	(4,71,28,073.15)	(71,09,940.13)	(1,74,55,548.53)
d) Other Manufacturing expenses	12,46,17,016.61	24,29,42,050.89	9,03,96,784.64	17,77,92,056.82
e) Employee benefit expenses	11,76,03,800.41	22,69,68,476.37	8,96,89,281.17	15,90,77,509.07
f) Finance Costs	1,27,41,974.27	2,41,47,824.09	96,86,061.52	1,89,90,952.71
g) Depreciation & amortisation expenses	5,57,60,132.57	10,41,00,274.02	3,94,87,087.08	7,25,42,401.22
h) Other expenses	12,00,46,401.76	21,30,53,217.79	7,29,72,641.58	12,99,09,292.90
Total Expenses	95,25,40,250.34	1,86,81,05,760.25	78,00,55,946.11	1,50,29,29,311.75
V. Profit before exceptional and extraordinary items and tax (III-IV)	19,89,63,452.80	41,05,65,389.30	18,03,86,877.27	34,30,13,947.15
VI. Exceptional Items	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	19,89,63,452.80	41,05,65,389.30	18,03,86,877.27	34,30,13,947.15
VIII. Extraordinary Items	-	-	-	-
IX. Profit before tax (VII-VIII)	19,89,63,452.80	41,05,65,389.30	18,03,86,877.27	34,30,13,947.15
X. Tax Expenses				
a) Current year tax	5,33,47,610.72	10,85,85,388.00	4,81,12,283.59	9,50,61,509.95
b) MAT credit/Deferred tax	(32,25,371.23)	(52,07,172.17)	15,07,121.76	(3,23,009.94)
XI. Profit (Loss) for the period from continuing operations (IX-X)	14,88,41,213.31	30,71,87,173.47	13,07,67,471.92	24,82,75,447.13
XII. Profit (Loss) from discounting operations				
XIII. Tax expenses of discounting operations				
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)				
XV. Net Profit/(Loss) for the period (XI+XIV)	14,88,41,213.31	30,71,87,173.47	13,07,67,471.92	24,82,75,447.13
XVI. Earning per share				
a) Basic	15.48	31.95	13.60	25.82
b) Diluted	15.48	31.95	13.60	25.82
XVIII. Paid up equity share capital	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	1,13,27,04,067.17	1,13,27,04,067.17	82,72,87,694.27	82,72,87,694.27

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 8th May 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.
- The above results for the half year ended 31st March, 2023 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2023 and the published unaudited year to date figure of the first half of the financial year

For KALRA RAI AND ASSOCIATES  
Chartered Accountants  
(FRN : 008859N)

**LAJPAT RAI KALRA**  
PARTNER  
Membership No. : 087438  
UDIN: 23087438BGVHEG7749  
Place : Chandigarh  
Date : 08/05/2023

**RAHUL BATRA**  
MANAGING DIRECTOR  
DIN : 02229234

**RAJNI REAR**  
COMPANY SECRETARY  
ACS24684

**NIPUN ARORA**  
CFO  
FCA514044

For and on Behalf of Board of Directors

**BETA DRUGS LIMITED**

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205  
Phone : 01795-236196 E-Mail : betabaddi@gmail.com  
CIN No. L24230HP2005PLC028969

**Consolidated Statement of Assets & Liabilities for the year ended on 31st March' 2023**

Particulars	As at 31st March' 2023	As at 30th Sep' 2022	As at 31st March' 2022
	Amount in Rs.	Amount in Rs.	Amount in Rs.
<b>1. EQUITY AND LIABILITIES</b>			
<b>(A) Shareholder's Funds</b>			
(a) Share Capital	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00
(b) Reserves and Surplus	1,13,27,04,067.17	98,41,17,417.43	82,72,87,694.27
(c) Money received against share warrants	-	-	-
<b>Sub-total-Shareholders' funds</b>	<b>1,22,88,41,967.17</b>	<b>1,08,02,55,317.43</b>	<b>92,34,25,594.27</b>
<b>(B) Non- Current Liabilities</b>			
(a) Long-term borrowings	6,97,38,034.01	6,68,54,967.00	11,82,61,500.00
(b) Deferred tax liabilities (Net)	-	-	-
(c) Other Long term liabilities	3,71,88,588.62	3,94,38,232.30	3,23,96,047.65
(d) Long term Provisions	1,82,87,036.00	1,43,19,603.00	1,47,47,479.00
<b>Sub-total-Non- current liabilities</b>	<b>12,52,13,658.63</b>	<b>12,06,12,802.30</b>	<b>16,54,05,026.65</b>
<b>(C) Current Liabilities</b>			
(a) Short-term borrowings	9,06,85,133.11	8,93,19,726.81	4,75,42,666.42
(b) Trade Payable	40,24,03,648.57	31,83,74,650.71	31,95,19,463.32
(c) Other current liabilities	9,53,69,362.80	9,81,02,925.63	8,63,29,640.17
(d) Short-term provisions	4,17,00,950.37	4,55,86,391.99	3,63,07,263.36
<b>Sub-total-current liabilities</b>	<b>63,01,59,094.85</b>	<b>55,13,83,695.14</b>	<b>48,96,99,033.27</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,98,42,14,720.65</b>	<b>1,75,22,51,814.88</b>	<b>1,57,85,29,654.20</b>
<b>2. ASSETS</b>			
<b>(A) Non-current assets</b>			
(a) Fixed assets			
(i) Property, Plant & Equipment	58,09,46,351.08	54,70,87,846.42	50,66,77,310.22
(ii) Intangible assets	4,66,22,694.40	4,22,87,948.79	4,28,73,439.35
(iii) Capital work-in-progress	-	-	-
(b) Non Current Investments	77,89,905.49	77,89,905.49	77,89,905.49
(c) Long Term Loan & Advance	5,95,02,750.97	4,59,16,056.58	4,43,02,141.08
(d) Other Non Current Assets	5,00,000.00	5,00,000.00	5,00,000.00
(e) Deferred tax Assets	1,20,06,496.08	87,81,124.95	67,99,324.01
<b>Sub-total-Non-current assets</b>	<b>70,73,68,198.02</b>	<b>65,23,62,882.24</b>	<b>60,89,42,120.15</b>
<b>(B) Current Assets</b>			
(a) Inventories	30,61,87,023.02	21,85,18,830.28	22,48,14,949.85
(b) Trade receivable	62,72,26,745.59	60,07,53,325.44	45,18,18,610.47
(c) Cash and bank balance	19,16,39,636.83	16,04,08,996.59	17,32,40,340.97
(d) Short-term loan and advances	6,09,02,324.96	4,48,45,085.88	4,47,68,829.69
(e) Other current assets	9,08,90,792.23	7,53,62,694.45	7,49,44,803.07
<b>Sub-total-current assets</b>	<b>1,27,68,46,522.63</b>	<b>1,09,98,88,932.64</b>	<b>96,95,87,534.05</b>
<b>TOTAL - ASSETS</b>	<b>1,98,42,14,720.65</b>	<b>1,75,22,51,814.88</b>	<b>1,57,85,29,654.20</b>

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 08th May' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES  
Chartered Accountants  
(FRN : 008859N)

LAJPAT RAI KALRA  
PARTNER  
Membership No. : 087438  
UDIN: 23087438BGVHEG7749  
Place : Chandigarh  
Date : 08/05/2023

For and on Behalf of Board of Directors

RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234

**BETA DRUGS LIMITED**

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

**Consolidated Cashflow Statement for the year ended on 31st March' 2023**

Particulars	As at 31 March' 2023	As at 30 Sep' 2022	As at 31 March' 2022
	Amount in Rs.	Amount in Rs.	Amount in Rs.
<b>A CASHFLOW FROM OPERATING ACTIVITIES</b>			
<b>Net Profit before tax and extraordinary items (as per Statement of Profit &amp; Loss)</b>	<b>41,05,65,389.30</b>	<b>21,16,01,936.49</b>	<b>34,30,13,947.15</b>
Adjustments for non Cash/Non trade items:			
Depreciation & Amortization Expenses	10,41,00,274.02	4,83,40,141.46	7,25,42,401.22
Finance Cost	2,41,47,824.09	1,14,05,849.82	1,89,90,952.71
Interest received	(66,29,830.03)	(29,51,597.54)	(45,17,345.97)
Other inflows/(outflows) of cash	(10,14,22,944.48)	(4,79,02,761.66)	(3,60,31,559.02)
<b>Operating profits before Working Capital Changes</b>	<b>43,07,60,712.90</b>	<b>22,04,93,568.57</b>	<b>39,39,98,396.09</b>
<b>Adjusted For:</b>			
(Increase)/Decrease in trade receivables	(17,54,08,135.12)	(14,89,34,714.97)	(11,30,54,240.47)
Increase/(Decrease) in trade payables	8,28,84,185.25	(11,44,812.61)	11,45,81,959.70
(Increase)/Decrease in inventories	(8,13,72,073.17)	62,96,119.57	(6,43,89,502.93)
Increase/(Decrease) in other current liabilities	90,39,722.63	1,17,73,285.46	78,78,557.18
(Increase)/Decrease in short term loans and advances	(1,61,33,495.27)	(76,256.19)	(2,05,27,837.83)
(Increase)/Decrease in other current assets	(1,59,45,989.16)	(4,17,891.38)	(2,22,10,428.29)
<b>Net Changes in working capital</b>	<b>(19,69,35,784.84)</b>	<b>(13,25,04,270.12)</b>	<b>(9,77,21,492.64)</b>
<b>Net cashflow from Operating Activities (A)</b>	<b>23,38,24,928.06</b>	<b>8,79,89,298.45</b>	<b>29,62,76,903.45</b>
<b>B CASHFLOW FROM INVESTING ACTIVITIES</b>			
Purchase of tangible/intangible assets	(18,21,18,569.93)	(8,81,65,187.10)	(19,42,74,774.76)
Interest received	66,29,830.03	29,51,597.54	45,17,345.97
Cash used for Non Current Investments	-	-	-
Cash used for Long Term Loans/Advances	(1,52,00,609.89)	(16,13,915.50)	(2,77,90,348.71)
<b>Net cash used in Investing Activities (B)</b>	<b>(19,06,89,349.79)</b>	<b>(8,68,27,505.06)</b>	<b>(21,75,47,777.50)</b>
<b>C CASHFLOW FROM FINANCING ACTIVITIES</b>			
Finance Cost	(2,41,47,824.09)	(1,14,05,849.82)	(1,89,90,952.71)
Increase in/(Repayment) of Short term Borrowings	4,31,42,466.70	4,17,77,060.40	1,21,37,556.48
Increase in/(Repayment) of Long term Borrowings	(4,37,30,925.02)	(4,43,64,348.35)	60,77,310.79
Increase/ (Decrease) in share capital	-	-	-
Increase/ (Decrease) in share premium	-	-	-
Other Inflows/ (Outflows) of cash	-	-	(89,60,000.00)
<b>Net cash used in Financing Activities (C)</b>	<b>(2,47,36,282.41)</b>	<b>(1,39,93,137.77)</b>	<b>(97,36,085.44)</b>
<b>D Net Increase/(Decrease) in cash &amp; cash equivalents (A+B+C)</b>	<b>1,83,99,295.86</b>	<b>(1,28,31,344.38)</b>	<b>6,89,93,040.51</b>
<b>E Cash &amp; Cash equivalents at beginning of period</b>	<b>17,32,40,340.97</b>	<b>17,32,40,340.97</b>	<b>10,42,47,300.46</b>
<b>F Cash &amp; Cash equivalents at end of period</b>	<b>19,16,39,636.83</b>	<b>16,04,08,996.59</b>	<b>17,32,40,340.97</b>
<b>G Net Increase/(Decrease) in cash &amp; cash equivalents (F-E)</b>	<b>1,83,99,295.86</b>	<b>(1,28,31,344.38)</b>	<b>6,89,93,040.51</b>

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 08th May' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants  
(FRN : 008859N)

LAJPAT RAI KALRA  
PARTNER

Membership No. : 087438

Place : Chandigarh

Date : 08/05/2023

For and on Behalf of Board of Directors

RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234



**KALRA RAI & ASSOCIATES**

**A Peer Review Firm**

**CHARTERED ACCOUNTANTS**

M : +91-98880-66743

Phone - 0172-4640667

E-mail : kalrarai@gmail.com

kalrarai667@hotmail.com

Head Office : Kothi No. 667, 1st Floor, Sector-43 A, Chandigarh - 160022

**Independent Auditor's Report on Audited standalone half yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**TO THE BOARD OF DIRECTORS OF,**

Beta Drugs Limited  
Village Nandpur,  
Lodhimajra Road  
Baddi Distt Solan  
H.P.-174101

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone half yearly financial results of **Beta Drugs Limited** (the company) for the half year ended **31<sup>st</sup> March, 2023** and the year to date results for the period from **1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i). are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii). give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the half year ended **31<sup>st</sup> March, 2023** as well as the year to date results for the period from **1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023**.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our opinion is not modified in respect of this matter.

**Branch Office Mohali :-**

Plot No. 775, Sector-82, JLPL, Mohali, Punjab-160082  
EMAIL : kalrarai@rediffmail.com

**Branch Office Delhi :-**

I-50, 4th Floor, Lagpat Nagar-1, New Delhi - 110024, Ph. : 011-43034803  
EMAIL : advphagunkalra@gmail.com | Cell : +91-77989-06173

## **Management's Responsibilities for the Standalone Financial Results**

These half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our

opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**For KALRA RAI & ASSOCIATES.**

**Chartered Accountants**

**(Firm's Registration No. 008859N)**



**LAJPAT RAI KALRA**

**(Partner)**

**(Membership Number: 087438)**

**UDIN: 23087438BGVHEH8160**

**Place: Chandigarh**

**Date: 08/05/2023**

**BETA DRUGS LIMITED**  
 Village Nandpur, LodhimaJra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205  
 Phone : 01795-236196 E-Mail : betabaddi@gmail.com  
 CIN No. L24230HP2005PLC028969

**Audited Standalone Financial Results for the year ended on 31st March' 2023**

Particulars	6 Months Ended on 31/03/2023 (Audited)	Year Ended on 31/03/2023 (Audited)	6 Months Ended on 31/03/2022 (Audited)	Year Ended on 31/03/2022 (Audited)
I. Revenue From Operations	79,90,69,508.92	1,57,87,45,873.45	65,31,73,676.05	1,24,84,68,429.04
II. Other Income	56,31,067.27	1,04,27,747.27	34,78,294.00	85,78,565.00
III. Total Revenue (I+II)	80,47,00,576.19	1,58,91,73,620.72	65,66,51,970.05	1,25,70,46,994.04
IV. Expenses				
a) Cost of Materials Consumed	44,41,93,216.81	86,46,83,818.09	36,14,03,627.57	69,86,31,569.86
b) Purchase of Stock-in-Trade	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	(2,61,42,428.76)	(3,16,95,413.75)	1,07,45,990.06	86,08,723.73
d) Other Manufacturing expenses	7,80,51,414.41	15,35,57,142.48	6,04,95,760.96	12,12,36,387.05
e) Employee benefit expenses	6,86,19,806.41	13,42,07,672.16	5,12,33,463.17	8,72,46,721.07
f) Finance Costs	53,81,250.82	83,66,109.28	20,07,927.29	41,22,446.22
g) Depreciation & amortisation expenses	3,22,72,261.88	6,19,48,358.39	2,98,22,585.21	5,46,77,970.56
h) Other expenses	7,98,95,450.73	14,60,11,366.41	4,30,25,804.62	8,09,06,768.85
Total Expenses	68,22,70,972.30	1,33,70,79,053.06	55,87,35,158.88	1,05,54,30,587.34
V. Profit before exceptional and extraordinary items and tax (III-IV)	12,24,29,603.89	25,20,94,567.66	9,79,16,811.17	20,16,16,406.70
VI. Exceptional Items	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	12,24,29,603.89	25,20,94,567.66	9,79,16,811.17	20,16,16,406.70
VIII. Extraordinary Items	-	-	-	-
IX. Profit before tax (VII-VIII)	12,24,29,603.89	25,20,94,567.66	9,79,16,811.17	20,16,16,406.70
X. Tax Expenses				
a) Current year tax	3,30,12,678.70	6,68,38,710.45	2,96,11,298.07	6,15,05,789.80
b) MAT credit/Deferred tax	(17,12,897.46)	(29,04,851.13)	(7,47,958.50)	(23,54,223.02)
XI. Profit (Loss) for the period from continuing operations (IX-X)	9,11,29,822.65	18,81,60,708.34	6,90,53,471.60	14,24,64,839.93
XII. Profit (Loss) from discounting operations				
XIII. Tax expenses of discounting operations				
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)				
XV. Net Profit/(Loss) for the period (XI+XIV)	9,11,29,822.65	18,81,60,708.34	6,90,53,471.60	14,24,64,839.93
XVI. Earning per share				
a) Basic	9.48	19.57	7.18	14.82
b) Diluted	9.48	19.57	7.18	14.82
XVIII. Paid up equity share capital	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	86,64,13,687.44	86,64,13,687.44	67,84,78,459.70	67,84,78,459.70

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 8th May 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.
- The above results for the half year ended 31st March, 2023 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2023 and the published unaudited year to date figure of the first half of the financial year.

For KALRA RAI AND ASSOCIATES

Chartered Accountants  
(FRN : 008859N)

LALPAT RAI KALRA  
PARTNER  
Membership No. : 087438  
UDIN: 23087438BGVHEH8160  
Place : Chandigarh  
Date : 08/05/2023

RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234

RAJNI BRAR  
COMPANY SECRETARY  
ACS24684

NIPUN ARORA  
CFO  
FCA514044

For and on Behalf of Board of Directors

**BETA DRUGS LIMITED**

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

**Standalone Statement of Assets & Liabilities for the year ended on 31st March' 2023**

Particulars	As at 31st March' 2023	As at 30th Sep' 2022	As at 31st March' 2022
	Amount in Rs.	Amount in Rs.	Amount in Rs.
<b>1. EQUITY AND LIABILITIES</b>			
<b>(A) Shareholder's Funds</b>			
(a) Share Capital	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00
(b) Reserves and Surplus	86,64,13,687.44	77,55,09,345.39	67,84,78,459.70
(c) Money received against share warrants			
<b>Sub-total-Shareholders' funds</b>	<b>96,25,51,587.44</b>	<b>87,16,47,245.39</b>	<b>77,46,16,359.70</b>
<b>(B) Non- Current Liabilities</b>			
(a) Long-term borrowings	3,72,87,825.36	4,21,47,956.00	5,15,08,245.00
(b) Deferred tax liabilities (Net)	-	-	-
(c) Other Long term liabilities	1,50,49,969.37	1,76,14,737.82	1,43,94,249.36
(d) Long term Provisions	1,08,12,022.00	95,57,629.00	99,85,505.00
<b>Sub-total-Non- current liabilities</b>	<b>6,31,49,816.73</b>	<b>6,93,20,322.82</b>	<b>7,58,87,999.36</b>
<b>(C) Current Liabilities</b>			
(a) Short-term borrowings	-	-	-
(b) Trade Payable	23,21,25,393.90	20,74,71,345.33	19,66,28,778.34
(c) Other current liabilities	5,31,94,311.53	5,50,40,914.16	4,24,63,374.95
(d) Short-term provisions	2,94,28,046.01	2,68,00,883.16	1,93,74,536.16
<b>Sub-total-current liabilities</b>	<b>31,47,47,751.44</b>	<b>28,93,13,142.65</b>	<b>25,84,66,689.45</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,34,04,49,155.61</b>	<b>1,23,02,80,710.86</b>	<b>1,10,89,71,048.51</b>
<b>2. ASSETS</b>			
<b>(A) Non-current assets</b>			
(a) Fixed assets			
(i) Property, Plant & Equipment	33,24,86,643.97	34,13,94,284.36	32,92,13,999.85
(ii) Intangible assets	1,52,31,151.40	1,12,81,137.74	1,13,57,083.35
(iii) Capital work-in-progress	-	-	-
(b) Non Current Investments	6,55,29,905.49	6,54,29,905.49	6,54,29,905.49
(c) Long Term Loan & Advance	6,77,71,564.40	6,11,82,823.76	6,88,84,261.86
(d) Other Non Current Assets	5,00,000.00	5,00,000.00	5,00,000.00
(e) Deferred tax Assets	89,23,345.75	72,10,448.28	60,18,494.61
<b>Sub-total-Non-current assets</b>	<b>49,04,42,611.01</b>	<b>48,69,98,599.63</b>	<b>48,14,03,745.16</b>
<b>(B) Current Assets</b>			
(a) Inventories	13,66,35,012.49	9,52,81,434.16	8,47,01,656.11
(b) Trade receivable	43,59,47,822.68	42,04,44,711.22	31,35,42,295.25
(c) Cash and bank balance	17,79,40,847.11	14,51,60,196.96	15,58,06,654.01
(d) Short-term loan and advances	2,85,00,578.37	2,47,18,224.45	1,90,25,193.98
(e) Other current assets	7,09,82,283.95	5,76,77,544.44	5,44,91,504.00
<b>Sub-total-current assets</b>	<b>85,00,06,544.60</b>	<b>74,32,82,111.23</b>	<b>62,75,67,303.35</b>
<b>TOTAL - ASSETS</b>	<b>1,34,04,49,155.61</b>	<b>1,23,02,80,710.86</b>	<b>1,10,89,71,048.51</b>

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 08th May' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants  
(FRN : 008859N)

LAJPAT RAI KALRA  
PARTNER  
Membership No. : 087438  
UDIN: 23087438BGVHEH8160  
Place : Chandigarh  
Date : 08/05/2023

For and on Behalf of Board of Directors

RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234

**BETA DRUGS LIMITED**

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Standalone Cashflow Statement for the year ended on 31st March' 2023

Particulars	As at 31 March' 2023	As at 30 Sep' 2022	As at 31 March' 2022
	Amount in Rs.	Amount in Rs.	Amount in Rs.
<b>A CASHFLOW FROM OPERATING ACTIVITIES</b>			
Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	25,20,94,567.66	12,96,64,963.77	20,16,16,406.70
Adjustments for non Cash/Non trade items:			
Depreciation & Amortization Expenses	6,19,48,358.39	2,96,76,096.51	5,46,77,970.56
Finance Cost	83,66,109.28	29,84,858.46	41,22,446.22
Interest received	(98,83,836.00)	(46,27,397.00)	(63,30,992.00)
Other inflows/(outflows) of cash	(5,61,84,164.19)	(2,68,27,560.74)	(2,13,21,459.33)
<b>Operating profits before Working Capital Changes</b>	<b>25,63,41,035.14</b>	<b>13,08,70,961.00</b>	<b>23,27,64,372.15</b>
Adjusted For:			
(Increase)/Decrease in trade receivables	(12,24,05,527.43)	(10,69,02,415.97)	(10,54,61,894.13)
Increase/(Decrease) in trade payables	3,54,96,615.56	1,08,42,566.99	6,41,89,639.88
(Increase)/Decrease in inventories	(5,19,33,356.38)	(1,05,79,778.05)	(77,51,337.30)
Increase/(Decrease) in other current liabilities	1,07,30,936.58	1,25,77,539.21	95,75,942.11
(Increase)/Decrease in short term loans and advances	(94,75,384.39)	(56,93,030.47)	8,86,984.93
(Increase)/Decrease in other current assets	(1,64,90,779.95)	(31,86,040.44)	(65,78,386.82)
<b>Net Changes in working capital</b>	<b>(15,40,77,496.01)</b>	<b>(10,29,41,158.73)</b>	<b>(4,51,39,051.33)</b>
<b>Net cashflow from Operating Activities (A)</b>	<b>10,22,63,539.13</b>	<b>2,79,29,802.27</b>	<b>18,76,25,320.81</b>
<b>B CASHFLOW FROM INVESTING ACTIVITIES</b>			
Purchase of tangible/intangible assets	(6,90,95,070.58)	(4,17,80,435.42)	(9,61,12,818.00)
Interest received	98,83,836.00	46,27,397.00	63,30,992.00
Cash used for Non Current Investments	(1,00,000.00)		
Cash used for Long Term Loans/Advances	11,12,697.46	77,01,438.10	(3,73,96,802.55)
<b>Net cash used in Investing Activities (B)</b>	<b>(5,81,98,537.12)</b>	<b>(2,94,51,600.32)</b>	<b>(12,71,78,628.55)</b>
<b>C CASHFLOW FROM FINANCING ACTIVITIES</b>			
Finance Cost	(83,66,109.28)	(29,84,858.46)	(41,22,446.22)
Increase in/(Repayment) of Short term Borrowings	-	-	(50,08,697.47)
Increase in/(Repayment) of Long term Borrowings	(1,35,64,699.63)	(61,39,800.54)	2,18,29,552.63
Increase/ (Decrease) in share capital	-	-	-
Increase/ (Decrease) in share premium	-	-	-
Other Inflows/ (Outflows) of cash	-	-	-
<b>Net cash used in Financing Activities (C)</b>	<b>(2,19,30,808.91)</b>	<b>(91,24,659.00)</b>	<b>1,26,98,408.94</b>
<b>D Net Increase/(Decrease) in cash &amp; cash equivalents (A+B+C)</b>	<b>2,21,34,193.10</b>	<b>(1,06,46,457.05)</b>	<b>7,31,45,101.20</b>
<b>E Cash &amp; Cash equivalents at beginning of period</b>	<b>15,58,06,654.01</b>	<b>15,58,06,654.01</b>	<b>8,26,61,552.81</b>
<b>F Cash &amp; Cash equivalents at end of period</b>	<b>17,79,40,847.11</b>	<b>14,51,60,196.96</b>	<b>15,58,06,654.01</b>
<b>G Net Increase/(Decrease) in cash &amp; cash equivalents (F-E)</b>	<b>2,21,34,193.10</b>	<b>(1,06,46,457.05)</b>	<b>7,31,45,101.20</b>

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 08th May' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES  
Chartered Accountants  
(FRN : 008859N)

LAJPAT RAI KALRA  
PARTNER  
Membership No. : 087438  
Place : Chandigarh  
Date : 08/05/2023

For and on Behalf of Board of Directors

RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234



# BETA DRUGS LIMITED

BDL/PKL/SEC/2023

8<sup>th</sup> May, 2023

To  
The Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, 5th Floor  
Plot no. C/I, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai — 400 051.

## SYMBOL-BETA

**Sub:** Declaration Pursuant to Regulation 33 (3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015

Dear Sir/Madam

In accordance with Regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we hereby declare that M/s Kalra Rai & Associates, Chartered Accountant (Firm Registration Number 008859N), Statutory Auditors of the Company have issued an Auditors Report with unmodified opinion on Standalone and Consolidated Audited Financial Results of the Company for the half year and year ended 31.03.2023 approved at the Board Meeting held on 8<sup>th</sup> May, 2023.

Kindly take the same on record.

Thanking You

Yours faithfully  
For Beta Drugs Ltd.

  
Rahul Batra  
Managing Director  
DIN NO. 02229234

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- [www.betadrugslimited.com](http://www.betadrugslimited.com)

E-Mail :- [info@betadrugslimited.com](mailto:info@betadrugslimited.com)